Literature DB >> 2470250

Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease.

J Sarosiek1, J Bilski, V L Murty, A Slomiany, B L Slomiany.   

Abstract

There is increased awareness that infection with Campylobacter pylori could be a major factor in the pathogenesis of gastric disease. Here, we present evidence that the extracellular protease elaborated by this bacteria, which causes degradation of gastric mucus, is inhibited by an antiulcer agent, colloidal bismuth subcitrate (CBS; De-Nol). The study was conducted with C. pylori cultured from antral mucosal biopsy specimens of patients undergoing gastroscopy. The grown colonies of bacteria were washed with saline, filtered through sterilization filter, dialyzed, and lyophilized. The powder was used as the enzyme source for proteolytic activity assay employing pig gastric mucus as substrate. Optimum enzymatic activity was obtained at 37 degrees C and at pH 7.0. The apparent Km of C. pylori protease with gastric mucus was 0.71 g/L. Analyses of the degradation products indicated that the protease caused extensive proteolysis of mucus glycoprotein polymer. Introduction of CBS to the incubation mixtures led to a reduction of the rate of mucus degradation. The rate of proteolysis inhibition was proportional to CBS concentration up to 1 X 10(-1) g/L, at which point a 37% reduction in mucus proteolysis was obtained. The Km value for proteolytic degradation of mucus by C. pylori protease in the presence of CBS was 1.25 g/L. The results suggest that CBS is capable of counter-acting the proteolysis of the protective gastric mucus layer by C. pylori.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470250

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Growth in and breakdown of purified rabbit small intestinal mucin by Yersinia enterocolitica.

Authors:  M Mantle; C Rombough
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

2.  Impact of Helicobacter pylori colonization on immunoreactive epidermal growth factor and transforming growth factor-alpha in gastric juice. Its potential pathogenetic implications.

Authors:  M Marcinkiewicz; B Van Der Linden; D A Peura; G Goldin; S Parolisi; J Sarosiek
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

3.  Peptic ulcer surgery in patients with liver cirrhosis.

Authors:  T Lehnert; C Herfarth
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

4.  Prostaglandin E2 in gastric mucosa of children with Helicobacter pylori gastritis: relation to thickness of mucus gel layer.

Authors:  G Oderda; M D'Alessandro; P Mariani; P Lionetti; M Bonamico; D Dell'Olio; N Ansaldi
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

5.  Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.

Authors:  D J Muñoz; C Tasman-Jones; J Pybus
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

6.  Helicobacter pylori: a Jordanian study.

Authors:  A H Latif; S K Shami; R Batchoun; N Murad; O Sartawi
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

7.  Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it.

Authors:  B A Hills
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

8.  Inhibitory Effects of 4-Guanidinobutyric Acid against Gastric Lesions.

Authors:  In Young Hwang; Choon Sik Jeong
Journal:  Biomol Ther (Seoul)       Date:  2012-03       Impact factor: 4.634

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.